Analystreport

CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its price target lowered by analysts at JPMorgan Chase & Co. from $10.00 to $9.00. They now have an "overweight" rating

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com